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Abstract 
 
A case of intoxication by haloperidol is reported. Haloperidol is a butyrophenone derivative 
commonly used in many hospital units as an antipsychotic agent. Adverse reactions due to 
haloperidol intoxication include drowsiness, blurred vision, extrapyramidal effects, tardive 
dyskinesia, tachycardia, hypotension and muscular rigidity. In August 2008, a 49 year-old female 
nurse started feeling various symptoms such as muscular rigidity, drowsiness and buccal 
dyskinesia. After 3 months, she was hospitalized for the worsening of these symptoms. Four 
months later, she showed once more the same symptoms. Two open water bottles from which the 
nurse used to drink in the hospital were confiscated and analyzed. Moreover, the nurse was asked 
to give a sample of her hair for executing the inherent toxicological analyses. Haloperidol was 
found in both bottles 1 and 2 at a concentration of 31.5 μg/mL and 43.6 μg/mL, respectively. Based 
on segmental hair analysis, it was deduced that the nurse consumed haloperidol in the 
approximate period from August 2008 to March 2009. The higher levels of haloperidol in hair were 
found in accordance with the periods of most severe appearance of symptoms, requiring the 
hospitalization of the nurse. The analysis of preservatives and excipients led us to conclude that 
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Haloperidol is a butyrophenone derivative synthesized in 1958 and first marketed in the United 
States in 1967. It is an effective antipsychotic agent commonly used in the treatment of 
schizophrenia and, more acutely, in the treatment of acute psychotic states and delirium [1]. The 
first molecules used as antipsychotic drugs, such as phenothiazines (promethazine, 
chlorpromazine) and butyrophenones (haloperidol) proved to cause a large number of side effects, 
but intoxications from their abuse were seldom reported as life threatening [2]. Adverse reactions 
to haloperidol intoxication include drowsiness, blurred vision, extrapyramidal effects, tardive 
dyskinesia, tachycardia, hypotension and muscular rigidity [1],[3] and [4]. Haloperidol is available in 
Italy mainly under the trade names of Serenase and Haldol. It is produced at different 
concentrations as tablets, oral solution, and injectable solution. This report describes a case of 
chronic intoxication involving haloperidol. 
2. Case report 
 
In August 2008, a 49 year-old female nurse started feeling various symptoms including muscular 
rigidity, drowsiness and buccal dyskinesia. Three months later, she was hospitalized for the 
aggravation of these symptoms. In March 2009, she showed once more the same symptoms. As 
she used to drink water from her own bottle stored in a shared refrigerator in the hospital, she 
claimed that some drugs could have been added to her water by someone working in the same 
unit. Some of her colleagues corroborated her suspects suggesting that the content of the bottle 
released an unusual smell. Therefore, she reported the episode to the justice. 
All the staff working in the unit had similar bottles stored in the same refrigerator and each bottle's 
owner was identified by his/her initials written on the bottle. Two open water bottles (residual 
volumes in bottles 1 and 2 were 280 mL and 135 mL, respectively) owned by the nurse and 
recently stored were confiscated and analyzed. In order to evaluate more directly the nurse 
exposition to drug of abuse or other xenobiotics, she was asked to give a sample of her hair for 
executing the inherent toxicological analyses. 
3. Materials and methods 
3.1. Specimen 
To execute a segmental analysis, proximal and distal portions of hair were identified. Assuming 
that hair growth rate generally ranges from 1.0 to 1.3 cm/month [5], a relationship between hair 
length and investigation chronology was obtained (Fig. 1). Hair length was about 14 cm and it was 
segmented as shown in Fig. 1. 
 
Fig. 1. Relationship between hair length and chronology of investigation. 
3.2. Chemicals and reagents 
Haloperidol and ethaverine were purchased from Sigma–Aldrich (Milan, Italy); methanol, t-butyl 
methyl ether (TBME) were supplied by Riedel-de Haën (Seelze, Germany); sodium hydroxide was 
obtained from Carlo Erba Reagents (Milan, Italy). 
3.3. Sample preparation 
For systematic search (screening) of toxic substances potentially present, 5 mL of water from each 
bottle was basified with 2 drops of NaOH 1 N and ethaverine was added as the internal standard at 
3 μg/mL concentration. After extraction with 10 mL of tert-butylmethylether, the organic layer was 
dried under nitrogen and the residue was dissolved with 50 μL of methanol. Qualitative 
identification of the organic components present in the bottles was performed using gas 
chromatography/mass spectrometry (GC–MS) with the mass spectrometer acquiring the spectra in 
the full scan mode (50–500 amu). 
Hair samples were decontaminated by washing with 2 mL of dichloromethane for 1 min twice and 
then were pulverized by a ball mill. Ethaverine at final concentration of 3 ng/mg was chosen as 
internal standard. Hair segments, approximately of 30–50 mg, were subjected to basic hydrolysis 
by adding 5 mL of NaOH 0.1 N and leaving the process proceed at 75 °C for 
30 min [6], [7], [8] and [9]. The resulting solution was extracted by 5 mL of tert-butylmethylether; 
the organic layer was separated and then dried under nitrogen. The resulting residue was 
reconstituted with 50 μL of methanol and a 1-μL aliquot was injected (split ratio of 10:1) into the 
GC/MS system operating in the SIM (selected ion monitoring) mode. 
3.4. GC/MS conditions 
GC–MS analyses were performed using a 6890N gas chromatograph from Agilent Technologies 
(Milan, Italy) equipped with a J&W HP-5 capillary column, 17 m × 0.200 mm × 0.33 μm. Helium 
was employed as the carrier gas at a constant pressure of 23.24 psi. The gas chromatograph oven 
temperature was set at 90 °C for 1 min and then raised to 180 °C with a 30 °C/min heating rate. 
The oven temperature was maintained at 180 °C for 7 min and then raised to 315 °C with a 
15 °C/min heating rate. The total run time was 23 min. The gas chromatograph injector and the 
transfer line were maintained at 280 °C. 
The chromatograph was coupled to a 5975-inert MSD from Agilent Technologies (Milan, Italy) with 
EI at 70 eV. Haloperidol was quantitatively determined in the two bottles and all hair segments by 
operating the mass spectrometer in the SIM mode acquisition. The fragment ions monitored for 
haloperidol were m/z 224 (target ion), 237 and 206 (qualifiers) [10], [11], [12] and [13], while for the 
internal standard (ethaverine) the diagnostic ions at m/z 366, 394 and 380 were chosen. 
3.5. Method validation 
A standard calibration curve was prepared by spiking blank hair at 0.5, 1.0, 5.0, 10.0 and 
20.0 ng/mg. LOD value for haloperidol was estimated as the analyte concentration whose 
response provided a S/N value equal to 3, as determined from the least abundant among qualifier 
ions. Estimated LOD numerical value was extrapolated from S/N value of the lowest concentration 
level (LCL) using the corresponding calibration curve. LOQ was consequently calculated as twice 
the LOD. Relative extraction recovery was determined by comparing the representative peak area 
of haloperidol extracted from hair spiked at the final concentration of 5.0 ng/mg with the peak area 
of a methanolic standard at the same concentration. Within-batch precision (expressed as percent 
variation coefficient, CV%) and accuracy (expressed as bias %), were assessed by extracting and 
analyzing a series of 5 hair samples spiked at 5.0 ng/mg. 
4. Results and discussion 
4.1. Validation results 
The calibration plots showed good linearity in the range 0.5–20 ng/mg with a correlation coefficient 
of 0.998. LOD was estimated at 0.25 ng/mg and, subsequently, LOQ was fixed at 0.50 ng/mg, 
which is also corresponding to the LCL. The extraction recovery was 71.3%. From the analysis of 
five replicates of hair samples spiked at the final concentration of 5.0 ng/mg, the within-batch 
precision resulted 7.7% and the accuracy (expressed as percent bias) resulted −1.1%. 
4.2. Experimental results 
Haloperidol was found in bottle 1 at a concentration of 31.5 μg/mL (total amount: 8.8 mg) and in 
bottle 2 at 43.6 μg/mL (total amount: 5.9 mg). 
Full scan analysis also revealed the presence of methylparaben, which is the methyl ester of p-
hydroxybenzoic acid and is commonly used as preservative in several pharmaceutical solutions. 
The n-propylparaben, also used in some haloperidol preparations, was not found in the water 
samples. 
Quantitative determinations of haloperidol in hair segments are reported in Table 1. Haloperidol 
was not present in segment D corresponding to a remote period likely preceding August 2008. 
 
Table 1. 
Results of segmental hair analysis. 
Specimen (diagnostic window) Haloperidol Length (cm) Concentration (ng/mg) 
Segment A 
(March–April 2009) 
Positive 1 1.4 
Segment B 
(November 2008–March 2009) 
Positive 5 0.5 
Segment C 
(August–October 2008) 
Positive 3 1.9 
Segment D 
(before August 2008) 
Negative 4–5 <LOD 
 
Haloperidol is available in Italy mainly under the name of Serenase, as tablets of 1 and 10 mg, oral 
solution of 2 and 10 mg/mL, and injectable solution of 2 mg/2 mL and 5 mg/2 mL. Under the name 
of Haldol, it is produced as 1 mg and 5 mg tablets, oral solution of 2 and 10 mg/mL and injectable 
solution of 5 mg. 
GC–MS analysis also revealed the presence of methylparaben, used as preservative in all oral 
solutions and in the 2 mg injectable solution of Serenase. 
Methylparaben is an anti-fungal agent commonly used as preservative in cosmetics, food, 
beverages and pharmaceuticals. It is readily absorbed from the gastrointestinal tract or through the 
skin [14]. Studies on the acute, subchronic, and chronic effects in rodents indicate that parabens 
are practically non-toxic[14] and [15]. No analytical evidence of the presence of other preservatives 
was observed. In particular, the presence of propylparaben, another preservative used in several 
preparations of Serenase and Haldol, could be excluded. As shown in Table 2, the unique 
pharmaceutical preparation, among the ones commercialized in Italy, containing methylparaben 
but not containing propylparaben is the 2 mg/mL oral solution of Haldol. Therefore, this is the 





Comparison of preservatives in different pharmaceutical preparations and in samples 
analyzed. 
Preparation Methylparaben Propylparaben 
Serenase (tablets) NO NO 
Serenase (oral solutions) YES YES 
Serenase (2 mg/2 mL solution for injection) YES YES 
Serenase (5 mg/2 mL solution for injection) NO NO 
Haldol (tablets) NO NO 
Haldol (2 mg/mL oral solution) YES NO 
Haldol (10 mg/mL oral solution) YES YES 
Haldol (5 mg/mL solution for injection) NO NO 
Bottle 1 YES NO 
Bottle 2 YES NO 
 
Segmental hair analysis (Table 1) revealed high concentration of haloperidol in segments A 
(March–April 2009) and C (August–October 2008) and significantly lower concentration in segment 
B (November 2008–March 2009). Based on these results, the nurse consumed haloperidol 
approximately in the period from August 2008 to March 2009 (segments A–C). Particularly, high 
concentrations of haloperidol in hair, found in segments A and C, correspond to the periods when 
the appearance of serious side effects due to haloperidol intoxication were ascertained (segment 
A: 1.4 ng/mg; segment C: 1.9 ng/mg). These levels appear lower than the concentrations 
previously found on psychiatric patients, which, however, referred to prospective studies with 
controlled drug administration on few subjects [16] and [17]. In real cases, where the intake of the 
drug is likely to be occasional and the doses are not predictable, it can be controversial to look for 
any relationship between the amount of drug detected in the hair and the quantity of the drug itself 
consumed by the subject. 
From the presence of haloperidol and methylparaben in the bottles from which the nurse used to 
drink her water, and from segmental hair analysis, also showing relevant concentrations of 
haloperidol, it can be concluded that someone was likely adding Haldol 2 mg/mL oral solution to 
these bottles, starting around August 2008, and that the nurse unwittingly consumed this drug by 
regular drinking from these bottles. The doses consumed were particularly high in the periods 
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